Pipeline Update: Drisapersen, GSK Report from Cold Spring Harbor Conference

PPMD received the email update below from Hans Schikan at Prosensa:

Dear all,

Today, at the Cold Spring Harbor conference in the US, Dr John Kraus of GSK gave an excellent presentation on the outcome of the 117 (DEMAND II) clinical trial. The primary endpoint in this exploratory study was met and a statistically and clinically meaningful difference of 35 meters in the six-minute walk test between the continuous dosing regimen of 6mg/kg per week and placebo was achieved at 24 weeks.

This is a great outcome, especially for the boys and their families affected by Duchenne muscular dystrophy.

Please see below an excerpt of articles which were published as a result of the data release.

With these results GSK and we made yet another step in the long journey to arrive at a possible treatment for Duchenne.

I would like to thank you for your continuous support and contribution, in whatever form.

Best regards,

Hans

 

http://www.fiercebiotech.com/story/glaxosmithkline-measures-38-mete...

 

http://www.pmlive.com/pharma_news/first_efficacy_data_for_gskprosen...

 

http://seekingalpha.com/article/1334611-muscular-dystrophy-drug-suc...

 

http://beta.fool.com/briannichols/2013/04/11/two-biotech-movers-wit...

 

http://www.investorvillage.com/smbd.asp?mb=1373&mn=33932&pt...

 

https://twitter.com/adamfeuerstein/statuses/322424341730033665

 

http://news.10jqka.com.cn/20130412/c533976896.shtml

 

http://mioby.ru/novosti/lechenie-myshechnoj-distrofii-dyushenna-dri...

 

Views: 585

Comment

You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service